Skip to main content

Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis

  • The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:381

Retraction Note: J Exp Clin Cancer Res

https://doi.org/10.1186/s13046-019-1324-7

The authors have retracted this article [1] because the bands shown in Fig. 5 panel D for GTP-RhoA/Control, GTP-RhoA/Sunitinib (2 and 64 nM) and GTP-RhoA/HM-3 (4.5 and 72 uM) are not data generated as part of this study. All authors agree to this retraction.

Reference

  1. 1.

    Hu J, Wang W, Liu C, et al. Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis. J Exp Clin Cancer Res. 2019;38:381. https://doi.org/10.1186/s13046-019-1324-7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hanmei Xu.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hu, J., Wang, W., Liu, C. et al. Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis. J Exp Clin Cancer Res 39, 35 (2020). https://doi.org/10.1186/s13046-020-1538-8

Download citation